Crohn’s & Colitis Foundation Perspectives

Diet and Nutrition in the Management of IBD

Host: Lu Ann Cahn Guest: James D. Lewis, MD, MSCE Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges? Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.

Emerging 'Bowel-Sparing' Procedures for Crohn's Disease

Host: Jennifer Caudle, DO Guest: Fabrizio Michelassi, MD As a gastrointestinal surgeon and Chairman of Surgery at Weill Cornell, Dr. Fabrizio Michelassi has witnessed the possible complications that can stem from Crohn's disease. He joins Dr. Jennifer Caudle to provide his perspective on new surgical approaches to treat strictures and fibrostenotic complications.

Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by MR Enterography

Guest: Yash Mittal, MD Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. Vipul Jairath, MD, PhD, Ingrid Ordas, MD, PhD, Guangyong Zou, PhD, Julian Panes, MD, Jaap Stoker, MD, PhD, Stuart A Taylor, MD, Cynthia Santillan, MD, Karin Horsthuis, MD, Mark A Samaan, MD, Lisa M Shackelton, PhD, Larry W Stitt, MSc, Pieter Hindryckx, MD, PhD, Reena Khanna, MD, William J Sandborn, MD ,Geert D'Haens, MD, PhD, Brian G Feagan, MD, Barrett G Levesque, MD, and Jordi Rimola, MD, PhD BACKGROUND: Magnetic resonance enterography is increasingly utilized for assessment of luminal Crohn's disease activity. The Magnetic Resonance Index of Activity and the London Index are the most commonly used outcome measures in clinical trials. We assessed the reliability of these indices and several additional items. METHODS: A consensus process clarified scoring conventions and identified additional items based on face validity. Four experienced radiologists evaluated 50 images in triplicate, in random order, at least 1 month apart, using a central image management system. Intra- and interrater reliability were assessed by calculating and comparing intraclass correlation coefficients. RESULTS: Intrarater intraclass correlation coefficients (95% confidence intervals) for the Magnetic Resonance Index of Activity, London, and London "extended" indices and a visual analogue ...

Success of Adalimumab Dose Escalation and De-Escalation in Ulcerative Colitis

Guest: Shail Govani, MD, MSc Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Saartje Van de Vondel, MD, Filip Baert, MD, PhD, Christine Reenaers, MD, PhD, Stijn Vanden Branden, MD, Leila Amininejad, MD, Pieter Dewint, MD, PhD, Wouter Van Moerkercke, MD, Jean-François Rahier, MD, PhD, Pieter Hindryckx, MD, PhD, Peter Bossuyt, MD, Marc Ferrante, MD, PhD, and Belgian IBD Research and Development (BIRD) BACKGROUND: Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required in 20%–25% of patients within 1 year. Real-life data suggest higher escalation rates. Attempts for dose de-escalation have not been studied yet. We assessed the need for, outcome of, and predictors of dose escalation and de-escalation in a large retrospective cohort of UC patients treated with ADM. METHODS: We included 231 consecutive patients from 10 Belgian centers initiating ADM treatment for active UC before September 1, 2015 (follow-up ≥1 year in each patient). We performed detailed chart review to identify variables associated with short-term clinical benefit (based on physician global assessment and absence of rectal bleeding at week 10), success ...

What IBD Professionals can Expect from the 2019 Annual Crohn’s & Colitis Congress

The Crohn’s & Colitis Foundation, in partnership with the American Gastroenterological Association, will hold their 2nd Annual Congress from February 7 - 9, 2019 at the Bellagio Hotel in Las Vegas. To give you an inside look into the premier meeting for all IBD professionals and researchers, here’s a special message from Michael Osso, President & CEO of the Crohn’s & Colitis Foundation. For more information and to register, please go to: www.crohnscolitiscongress.org.